论文部分内容阅读
目的探讨转化生长因子β激活激酶1(transforming growth factorβ-activated kinase 1,TAK1)在人非小细胞肺癌(non-small cell lung cancer,NSCLC)中的表达及意义。方法行手术治疗NSCLC患者90例,采用免疫组织化学方法检测90份NSCLC组织(NSCLC组)及40份癌旁正常组织(对照组)中TAK1蛋白表达,分析TAK1表达量与NSCLC患者临床病理特征的关系。结果NSCLC组TAK1阳性表达率(80.0%)高于对照组(17.5%),差异有统计学意义(P<0.05);NSCLC患者TAK1阳性率在不同临床分期(χ~2=7.647,P=0.006)、分化程度(χ~2=10.852,P=0.004)及有无淋巴结转移(χ~2=5.511,P=0.019)上差异有统计学意义。结论 TAK1可能与NSCLC的发生、发展有关。
Objective To investigate the expression and significance of transforming growth factor beta-activated kinase 1 (TAK1) in human non-small cell lung cancer (NSCLC). Methods Ninety cases of NSCLC patients underwent surgical treatment. Immunohistochemistry was used to detect the expression of TAK1 protein in 90 NSCLC tissues (NSCLC group) and 40 adjacent normal tissues (control group). The expression of TAK1 and the clinicopathological features of NSCLC patients were analyzed. relationship. Results The positive expression rate of TAK1 was higher in NSCLC group (80.0%) than in control group (17.5%) (P<0.05). The positive rate of TAK1 in NSCLC patients was in different clinical stages (χ~2=7.647, P=0.006). The difference in the degree of differentiation (χ~2=10.852, P=0.004) and the presence or absence of lymph node metastasis (χ~2=5.511, P=0.019) was statistically significant. Conclusion TAK1 may be related to the occurrence and development of NSCLC.